Skip to main content

Table 4 Comparison of the characteristics of postmenopausal patients with sarcomas and leiomyomas who underwent surgery for uterine mesenchymal tumors

From: Analysis of uterine corporeal mesenchymal tumors occurring after menopause

  Total Sarcoma Benign p-value
Number of patients 40 100% 11 27.5% 29 72.5%  
Age(yr) 62.5 (50–81) 66 (50–80) 60 (51–81) 0.12
Age at menopause(yr) 51 (49–57) 52 (49–55) 51 (49–57) 0.523
BMI 22.6 (15.4–39.4) 22.4 (19–27.8) 22.6 (15.4–39.4) 0.654
Tumor size(cm) 10 (2.6–30) 10 (6–30) 9 (2.6–24) 0.2
Serum CA125(U/ml) 13 (5.6–234.1) 18.3 (11–234.1) 11.5 (5.6–44.2) 0.054
Serum CA19–9(U/ml) 6.4 (1.2–303) 6 (2–19.9) 6.5 (1.2–303) 0.94
Serum CEA(ng/ml) 1.45 (0.4–6.3) 1.5 (0.5–4.9) 1.4 (0.4–6.3) 0.598
Serum LDH(IU/l) 203 (125–629) 225 (156–629) 202 (125–300) 0.08
Abnormal bleeding 7 17.5% 3 27.3% 4 13.8% 0.399
Abnormal signal on MRI 22 55% 11 100% 11 37.9% < 0.001*
  1. *P < 0.05
  2. Values are presented as median (range), or number (%). BMI Body Mass Index, CA125 Cancer antigen 125, CA19–9 Carbohydrate antigen 19–9, CEA Carcinoembryonic antigen, LDH Lactate dehydrogenase, MRI Magnetic resonance imaging